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Abstract
Background: Transthyretin (TTR) amyloidosis is a hereditary disease with a complex genotype-phenotype correlation. We
conducted a literature survey to define the clinical landscape of TTR amyloidosis across populations worldwide. Then, we
investigated whether the genetically determined TTR expression differs among human populations, contributing to the
differences observed in patients. Polygenic scores for genetically determined TTR expression in 14 clinically relevant
tissues were constructed using data from the GTEx (Genotype-Tissue Expression) project and tested in the samples from
the 1,000 Genomes Project.
Results: We observed differences among the ancestral groups and, to a lesser extent, among the investigated populations
within the ancestry groups. Scandinavian populations differed in their genetically determined TTR expression of skeletal
muscle tissue with respect to Southern Europeans (p = 6.79*10−6). This is in line with epidemiological data
related to Swedish and Portuguese TTR Val30Met endemic areas. Familial amyloidotic cardiomyopathy (TTR deposits
occur primarily in heart tissues) presents clinical variability among human populations, a finding that agrees with the
among-ancestry diversity of genetically determined TTR expression in heart tissues (i.e., Atrial Appendage p = 4.55*10−28;
Left Ventricle p = 6.54*10−35).
Conclusions: Genetically determined TTR expression varied across human populations. This might contribute to the
genotype-phenotype correlation of TTR amyloidosis.
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Background
Transthyretin (TTR) amyloidosis (OMIM: 105210) is a
rare, life-threatening, progressively debilitating, auto-
somal dominant condition characterized by extracellular
deposition of TTR-derived amyloid fibrils in peripheral
and autonomic nervous system, heart, and other organs,
leading to tissue damage and organ failure [1, 2]. The
disorder is caused by point mutations in the TTR gene
(NM_000371) located in chromosome region 18q12.1 [3].
The disease presents multiple clinical signs, including
peripheral neuropathy (sensory and motor), autonomic
neuropathy, gastrointestinal impairment, cardiomyopathy,
nephropathy, and ocular deposition [4]. While these
symptoms may be present in patients with different TTR
mutations, phenotypes are not always concordant and the
same point mutation may be associated with different
signs/symptoms [5]. The clinical heterogeneity of the car-
riers of the TTR amyloidogenic mutations is particularly
relevant from a population perspective. The most striking
example of this inter-population diversity is the Val30Met
mutation [rs28933979, c.148G > A, p.Val50Met], which is
one of the leading causes of TTR amyloidosis [6, 7]. In the
two European Val30Met endemic areas (i.e., Portugal and
Sweden), Val30Met patients show two distinct phenotypic
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presentations. In Val30Met Portuguese families, the dis-
ease shows early-onset, strong severity, and high pene-
trance [8, 9], whereas Val30Met Swedish patients have
late-onset, intermediate severity, and low penetrance [10].
This complex genotype-phenotype correlation indicates
that the clinical presentation is not only regulated by the
disease-causing mutation. The amyloidogenic mutation is
the cause of the disease, but other factors contribute to
the modulation of the disease phenotype [11–13]. Our
previous investigations focused on the role of non-coding
variation in the genotype-phenotype correlation of TTR
amyloidosis. We observed an enrichment for non-coding
regulatory variants located in heart-related transcription-
factor binding sites in African populations, suggesting a
contribution to the cardiomyopathy observed in patients
of African ancestry [12]. We also investigated the haplo-
type structures of Val30Met and Val122Ile [rs76992529,
c.424G >A, p.Val142Ile] mutations, observing in both
cases independent haplotypes carrying the same disease-
causing mutation [14, 15]. Non-coding variation regulates
genome functions, especially through its key role in tran-
scriptional mechanisms across human tissues [16]. On this
basis, we hypothesized that, in presence of an amyloido-
genic mutation, the non-coding regulation of TTR gene
expression across tissues contributes the distribution of
TTR-derived amyloid fibrils and, consequently, the disease
presentation. In accordance with this hypothesis, a recent
study demonstrated that, although the liver is the main
TTR organ source, TTR gene expression in other tissues
can also be involved in the processes related to the disease
phenotype [17].
Recent studies have focused on how gene expression
regulates relevant biological processes and how its alter-
ation can lead to the onset of diseases [18]. The
Genotype-Tissue Expression (GTEx) Project is investi-
gating genetic variation in relation to gene expression in
human tissues [19]. GTEx data (available at http://
www.gtexportal.org/) provide information about the rela-
tionship between genetic variations and gene expression
in 43 different human tissues [20]. The effects of genetic
variants can be used to estimate the genetically deter-
mined gene expression to investigate the role of gene ex-
pression in multiple tissues with respect to disease
pathogenesis [21, 22]. Accordingly, the analysis of the
genetically determined TTR expression can help to dis-
cern its involvement in human tissues with respect to
the genotype-phenotype correlation of TTR amyloidosis.
Results
Results from literature review
We identified 88 worldwide disease-causing mutations with
information regarding the ancestry (Additional file 1). Our
findings indicated that Europeans have the highest
number of TTR mutations (N = 60), followed by East
Asians (N = 27), Americans (N = 20), Central-South
Asians (N = 8) and Africans (N = 3). The ancestry was
not specified for the remaining amyloidogenic muta-
tions. Few mutations are reported in multiple ancestry
groups (e.g., Val30Met and Val122Ile) and several
symptoms are reported for patients with different an-
cestries and different mutations (e.g., cardiomyopathy
and sensorimotor neuropathy) (Additional file 1).
However, clinical signs partially occur in an ancestry-
specific manner with respect to the amyloidogenic
mutation reported (Additional file 1).
Genetically-predicted TTR expression
As introduced above, we used the data from GTEx
Project [19] to build polygenic scores associated with
TTR expression in 14 human tissues and tested them in
the samples from the 1,000 Genomes Project [23] consid-
ering both among-ancestry and within-ancestry analyses.
A detailed description of procedures used is reported in
the method section.
Among-ancestry comparisons
The among-ancestry comparisons showed very signifi-
cant differences (p < 2.89*10−9) for genetically predicted
TTR expression scores for all investigated tissue
(Additional file 2) with the exception of the Esophagus –
Muscularis tissue (p > 0.05). Post-hoc pairwise analysis of
the among-ancestry comparisons indicated that these
significant differences are generally present across mul-
tiple ancestries and are not due to the diversity of a sin-
gle population (Additional file 3). The only exception to
this general trend is the Colon - Transverse tissue where
the significant result is exclusively driven by the differ-
ence between African and non-African populations
(p = 5.44*10−11).
Within-ancestry comparisons
Within-ancestry comparisons showed less tissue- and
ancestry-specific differences than among-ancestry com-
parisons (Fig. 1). Significant differences were observed
within European ancestry (Colon – Transverse p = 0.002
and Muscle – Skeletal p = 6.79*10−6), within Eastern
Asian ancestry (Nerve - Tibial p = 7*10−5), and within
American ancestry (Colon - Transverse p = 3.2*10−7,
Colon – Sigmoid p = 2*10−4, Muscle – Skeletal p = 9*10
−4, and Skin - Sun Exposed (Lower leg) (p = 6*10−4). The
significant results of the post-doc pairwise analysis are
reported in Fig. 2. In European populations, the diversity
of TTR expression scores in the significant tissues is
driven by North–south variability, with the most signifi-
cant diversity between Scandinavian populations (i.e.,
the 1,000 Genomes Project FIN population) and the
other European samples (Additional file 4). In Eastern
Asian samples, the diversity for TTR expression scores
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in Nerve - Tibial tissue is driven by differences of
Vietnamese populations (i.e., the 1,000 Genomes Project
KHV population) with respect to Japanese and Chinese
populations (Additional file 5). Regarding the tissues
identified in the American samples, the diversity of TTR
expression scores is driven by differences between
Peruvian population (i.e., the 1,000 Genomes Project
PEL population) and other American populations
(Additional file 6). Permutation analysis confirmed that
all within-ancestry observed differences significantly di-
verge from the null distribution of the permuted results
(Fig. 3). The observed Z-scores are located in extremely
marginal positions with respect to the null distribution of
the Z-scores generated by the random permutations.
No significant differences were observed for African
ancestry (nominal significance for Colon –Transverse,
Esophagus – Muscularis, Liver, Muscle – Skeletal, Stom-
ach, and Small Intestine; Additional file 7) and Central-
South Asian ancestry (nominal significance for the Skin
- Sun Exposed (Lower leg) tissue; Additional file 8).
Discussion
Our literature review indicated that few mutations were
observed in multiple ancestral groups (e.g., Val30Met
and Val122Ile). However, these are the mutations de-
tected in most patients affected by TTR amyloidosis and
the corresponding clinical signs mainly occur with
ancestry-specific patterns. Although these ancestry dif-
ferences are likely biased by the rare disease prevalence
and the variability of the clinical practice guidelines
across different countries, the inter-population diversity
of the molecular mechanisms involved in the genotype-
phenotype correlation surely plays an important role in
the clinical presentation observed in patients with differ-
ent ancestry backgrounds. Our previous investigations
indicated that TTR non-coding regions are affected by
human population diversity with potential consequences
on gene regulation [12, 14, 15]. Our hypothesis is in
agreement with many studies about the regulatory role
of non-coding variation on gene expression and other
gene functions [24, 25]. TTR gene expression showed a
relevant inter-individual variability across human tissues
(Fig. 4), and the related tissue-specific regulatory mecha-
nisms is likely to be one of the processes involved in the
disease genotype-phenotype correlation. Our current
findings based on a large multi-ethnic cohort (N = 2,504)
and gene expression information from multiple human
tissues (N = 14) provide novel insight regarding the
regulatory mechanisms of TTR gene. Indeed, very few
investigations explored mechanisms related to gene ex-
pression in TTR amyloidosis due to limited availability
Fig. 1 Heatmap of the Kruscal-Wallis results related to the within-ancestry
comparisons. The colors refer to different significance levels (red:
Bonferroni-corrected significance; yellow: Nominal significance).
(AFR: Africa, EUR: Europe, EAS: East Asia, SAS: South Asia, AMR: America)
Fig. 2 Heatmap of the Kruscal-Wallis post-hoc analysis results of within-
ancestry comparisons. The colors refer to different significance levels (red:
Bonferroni-corrected significance; yellow: Nominal significance).
Information about population definitions are available at http://www.1000
genomes.org/about (EUR: Europe, EAS: East Asia, AMR: America)
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Fig. 3 Distribution of the z-scores generated from 100,000 random permutations with respect to the z-scores observed in the Kruscal-Wallis post-hoc
analysis of within-ancestry comparisons. (EUR: Europe, EAS: East Asia, AMR: America)
Fig. 4 TTR gene expression across the 14 clinically relevant tissues investigated the present study. This figure was extracted from the GTEx portal
available at http://www.gtexportal.org/home/
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of tissue samples from affected patients. In 2014, Norg-
ren and colleagues [26] observed that TTR gene expres-
sion is significantly higher in patients’ liver than in
healthy controls. They hypothesized an impaired endo-
plasmatic reticulum-associated degradation and posited
that the endoplasmatic reticulum-assisted folding was
caused by an overload of mutated TTR protein.
Recently, an in vitro study demonstrated that Schwann
cells can contribute to neurodegeneration in TTR amyl-
oidosis through the local expression of mutated TTR
[17]. Accordingly, TTR gene expression patterns across
different tissues, including source and target organs, can
contribute to the symptoms observed in patients. To
provide novel information regarding this topic, we used
data from the GTEx project and the 1,000 Genomes
Project. Specifically, we calculated tissue-specific scores
to link genetic variability to TTR gene expression and
analyzed the inter-population variability considering
both differences among ancestries and among popula-
tions within the same ancestral groups. Our data con-
firmed that non-coding variations affect gene expression
with tissue-specific patterns and that human populations
have significant differences. Due to the very low disease
prevalence and relatively few reports regarding TTR
amyloidosis, it is difficult to conduct effective compari-
sons between epidemiological and molecular data. How-
ever, in some cases, we observed consistency between
clinical evidences and our computational results.
Since Val30Met is the most recurring mutation in pa-
tients with TTR amyloidosis, numerous epidemiological
studies investigated its distribution across human popu-
lations. As mentioned above, the features of the two en-
demic Val30Met foci in Europe are well known: Swedish
patients with late-onset, intermediate severity, and low
penetrance vs. Portuguese patients with early-onset, se-
vere symptoms, and high penetrance [7]. Our molecular
outcomes are consistent with these epidemiological data:
Scandinavian populations (i.e., the 1,000 Genomes Pro-
ject FIN) showed the strongest difference with respect to
southern European populations (i.e., the 1,000 Genomes
Project IBS and TSI) for Muscle – Skeletal tissue.
The second most recurrent TTR mutation is
Val122Ile that reaches 4% in African-Americans and
West Africans [27]. This mutation is mainly associ-
ated with familial amyloidotic cardiomyopathy due to
TTR deposits in heart tissue [28]. In our literature
survey, we observed that Val122Ile was reported in
multiple ancestry groups with high heterogeneity in
the disease features related to the familial amyloidotic
cardiomyopathy (e.g., onset and severity). Regarding
heart tissues (i.e., Heart - Atrial Appendage; Heart -
Left Ventricle), we observed significant differences
among the ancestry groups investigated that may be in
agreement with the epidemiological data collected.
Besides this consistent overlapping of our results with
known epidemiological evidences, we observed other
strong differences within some ancestry groups that may
support future epidemiological investigations. In the East
Asian group, our analysis revealed a significant differ-
ence between Vietnamese population (i.e., the 1,000
Genomes Project KHV population) and Japanese and
Chinese groups (i.e., the 1,000 Genomes Project JPT and
CHS populations) that agrees with previous studies on
the genetic structure of East Asian populations [29].
Regarding TTR amyloidosis, Japan is one of the endemic
foci of the disease with a prevalence of one per million,
and different mutations have been identified along with
a marked heterogeneity in the disease phenotypic ex-
pression [30]. Chinese cases with different TTR muta-
tions (e.g., Gly83Arg, Ile107Met) have also been
identified [31]. To our knowledge, no reports have been
published on Vietnamese or other South-Eastern Asian
populations. Further studies on Eastern Asian patients
may indicate strong differences within this ancestry
group in accordance with our data. Another intriguing
result is related to the admixed American populations of
the 1,000 Genomes Project (i.e., CLM, MXL, PEL, PUR).
These population clusters are an admixture of European,
African, and Native American ancestry and a recent
study indicated strong differences in the admixture pro-
portions [32]. Previous studies demonstrated that haplo-
type structure of admixed populations play an important
role in gene regulatory mechanisms [33, 34]. Our
current data suggested that admixture differences could
contribute to the heterogeneity observed among patients
from admixed American populations.
Beyond TTR hereditary amyloidosis, non-coding vari-
ants associated with TTR expression could be involved
in the pathogenesis of the non-inherited form of TTR
amyloidosis, known as senile systemic amyloidosis. This
disorder is caused by a deposition of fibrils derived from
TTR in subjects that do not carry amyloidogenic muta-
tions. It occurs as cardiomyopathy in elderly men with
European ancestry, and TTR amyloid fibrils can be
found in the hearts of the 25% of elderly individuals over
80 years of age [35]. A recent study provided suggestive
evidences regarding the role of non-coding regulatory
regions in wild-type TTR amyloidosis [36]. Together
with these previous findings, our data suggest that TTR
non-coding variation and its effect on transcription
regulation are strong candidates as casual factors in the
non-inherited form of TTR amyloidosis.
Conclusions
In conclusion, the current study advances the knowledge
of TTR amyloidosis in terms of both data regarding the
inter-population variability of the disease and method-
ology that can be applied. However, our results are
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affected by some limitations. The GTEx Project investigated
a multi-ethnic cohort with limited sample size that cannot
completely detect the effects of genetic variability on gene
expression across human populations. Although our find-
ings provided insights regarding TTR expression regulation,
our analysis is based on data from general-population co-
hort that included subjects without TTR mutations. There-
fore, our findings do not account for interactions between
the amyloidogenic mutation and TTR gene regulation,
which likely contribute to TTR expression variability in the
affected patients. Due to the large sample size (N = 2,504)
used to investigate the role of non-coding variation in the
regulation of TTR expression across human tissue, the pos-
sibility to experimentally confirm our findings is currently
limited by cost and sample availability. Finally, in addition
to TTR gene expression, other mechanisms can also con-
tribute to the genotype-phenotype correlation of the dis-
ease, and our data may only reflect one of the molecular
processes involved. Further in vivo and in vitro investiga-
tions are warranted to follow up our results and confirm
the role of genetically determined TTR expression in the
disease onset and progression.
Methods
Literature survey
To delineate the genetic and clinical landscape of this
disease among worldwide populations, we used PubMed
to identify 938 scientific articles related to TTR amyloid-
osis. The literature search was performed in January
2016 with the following key words: “TTR”, “TTR amyl-
oidosis”, “TTR mutation”, “TTR gene”. Of these 938 pa-
pers, we selected studies (n = 144) with information
concerning clinical signs and TTR mutations of patients
investigated. Finally, we partitioned the selected articles
by ancestral group: Africa (Africans and African-
Americans patients), Europe, Central-South Asia, East
Asia, and America. In the American group, we included
those studies involving patients of Hispanic ethnicity
and/or Native American ancestry. In accordance with
the vast majority of the literature regarding TTR amyl-
oidosis, we named each TTR mutation in accordance
with the protein change in the mature protein. We also
reported rsID (when available) and the protein change in
the protein precursor (Additional file 1).
Genotype and expression data
Phase 3 of the 1,000 Genomes Project was considered the
reference genotype dataset [23]. We obtained the VCF
(Variant Call Format) file of the 40 Kb region, which in-
cludes upstream region, TTR CDS, and downstream region
(GRCh37/hg19 chr 18: 29155000–29195000). Detailed
information about population definitions is available at
http://www.1000genomes.org/about. The VCF file of the in-
vestigated region can be downloaded from the following
link: http://phase3browser.1000genomes.org/Homo_sa
piens/Location/View?r=18%3A29155000-29195000.
The GTEx Version 6 data were used as reference data-
sets for genetically determined gene expression [20].
GTEx cohort includes individuals with different ancestry
and it was previously used for population comparisons
[37]. We extracted information regarding the effects (i.e.,
beta values and p-values) of genetic variants on TTR
gene expression in 14 clinically relevant tissues among
those available in GTEx data: Colon – Transverse; Colon –
Sigmoid; Esophagus –Muscularis; Esophagus – Mucosa;
Heart - Atrial Appendage; Heart - Left Ventricle; Liver;
Muscle – Skeletal; Nerve – Tibial; Stomach; Small Intestine
- Terminal Ileum; Adipose – Subcutaneous; Cells - Trans-
formed fibroblasts; and Skin - Sun Exposed (Lower leg).
Finally, we identified 132 variants (131 non-coding
variants e 1 coding variant) presenting comprehensive
information for the 14 tissues. In the Additional file 9, we
reported the GTEx statistics used to build the tissue-
specific polygenic scores. The original GTEx data used in
the current study can be obtained from the following link:
http://www.gtexportal.org/home/testyourown.
Data analysis
The first step of the analysis was to build polygenic scores
for genetically determined TTR expression for each of the
14 clinically relevant tissues. These tissue-specific polygenic
scores were a sum of alleles associated with TTR expression
in a specific tissue, weighted by effect sizes. As mentioned
above, we used 1,000 Genomes Project data as reference
dataset for LD (Linkage Disequilibrium) structure and hu-
man genetic variability and GTEx data as reference datasets
to determine the effect of genetic variants upon TTR ex-
pression. We conducted a LD clumping analysis using Plink
1.07 toolset [38]. We included in the analysis SNPs (Single
Nucleotide Polymorphisms) with at least a trend effect (p ≤
0.1) on TTR expression and considered standard LD param-
eters (r2 = 0.5, and region size = 10Kb). The LD clumping
was conducted with respect to two perspectives: compari-
sons among ancestry groups (i.e., among-ancestry compari-
sons) and comparisons across population within ancestry
groups (i.e., within-ancestry comparison). Accordingly, we
calculated 14 tissue-specific clumped datasets for each an-
cestry (i.e., LD information across all ancestry) and 14
tissue-specific clumped datasets for the populations within
each ancestry groups (i.e., LD information specific for each
ancestry group). All calculated datasets consisted of genetic
variants in non-coding regions of TTR gene and the com-
position of each dataset is reported in the Additional file 10.
We used these tissue-specific clumped datasets to calculate
the polygenic scores for genetically determined TTR expres-
sion on the basis of effect-allele count and allele effect size.
The among-ancestry and within-ancestry comparisons
were performed using the Kruskal-Wallis test. This
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non-parametric test permitted us to verify whether the
differences observed among ancestries and among popu-
lations within the same ancestries were statistically sig-
nificant. To deepen the findings obtained from the
Kruskal-Wallis analysis, we used Dunn’s test for the
post-hoc pairwise comparisons. Bonferroni correction
accounting for the number of tissues tested was applied
to adjust the results for multiple-testing comparisons.
Finally, we further quantified the significance of the ob-
served within-ancestry differences, conducting a permu-
tation analysis. Specifically, we performed 100,000
permutations of the individual tissue-specific polygenic
scores with respect to their population origins and tested
whether the observed differences were significantly dif-
ferent from the null distribution of the permuted results.
Additional files
Additional file 1: Inter-ethnic clinical diversity associated with TTR mutations.
Each mutation is named in accordance of the missense substitution in the
mature protein. For each mutation, rsID and protein change in the protein
precursor is also reported. (PDF 137 kb)
Additional file 2: Kruscal-Wallis analysis among ancestral groups. For
each ancestral group the synthesis of the TTR expression scores, in terms
of median, minimum and maximum, for each tissue involved in TTR
amyloidosis is reported. (PDF 124 kb)
Additional file 3: Heatmap of the Dunn’s post-hoc test among the
ancestral groups. The colors refer to different significance levels.
Detailed information about population definitions is available at
http://www.1000genomes.org/about (AFR: Africa, EUR: Europe, EAS:
East Asia, SAS: South Asia, AMR: America). (PDF 201 kb)
Additional file 4: Kruscal-Wallis analysis within the European ancestral
group. For each population the synthesis of the TTR expression scores, in
terms of median, minimum and maximum, for each tissue involved in
TTR amyloidosis is reported. Detailed information about population definitions
is available at http://www.1000genomes.org/about. (PDF 102 kb)
Additional file 5: Kruscal-Wallis analysis within the Eastern Asian ancestral
group. For each population the synthesis of the TTR expression scores, in
terms of median, minimum and maximum, for each tissue involved in TTR
amyloidosis is reported. Detailed information about population definitions is
available at http://www.1000genomes.org/about. (PDF 101 kb)
Additional file 6: Kruscal-Wallis analysis within the American ancestral
group. For each population the synthesis of the TTR expression scores, in
terms of median, minimum and maximum, for each tissue involved in
TTR amyloidosis is reported. Detailed information about population definitions
is available at http://www.1000genomes.org/about. (PDF 115 kb)
Additional file 7: Kruscal-Wallis analysis within the African ancestral
group. For each population the synthesis of the TTR expression scores, in
terms of median, minimum and maximum, for each tissue involved in
TTR amyloidosis is reported. Detailed information about population definitions
is available at http://www.1000genomes.org/about. (PDF 90 kb)
Additional file 8: Kruscal-Wallis analysis within the Southern Asian
ancestral group. For each population the synthesis of the TTR expression
scores, in terms of median, minimum and maximum, for each tissue involved
in TTR amyloidosis is reported. Detailed information about population
definitions is available at http://www.1000genomes.org/about. (PDF 101 kb)
Additional file 9: List of the selected 132 variants (GRCh37/hg19) with
comprehensive information (p-value and effect size) for the 14 investigated
tissues. (PDF 138 kb)
Additional file 10: A) Clumped datasets for the African ancestry. Colors
refer to variants in the LD blocks (r2 > 0.5; different colors represent
different LD blocks) and X = presence of a variant in a specific dataset
after the LD clumping analysis. B) Clumped datasets for the European
ancestry. Color refer to variants in the LD block (r2 > 0.5; different colors
represent different LD blocks) and X = presence of a variant in a specific
dataset after the LD clumping analysis. C) Clumped datasets for the
Eastern Asian ancestry. Colors refer to variants in the LD blocks (r2 > 0.5;
different colors represent different LD blocks) and X = presence of a variant
in a specific dataset after the LD clumping analysis D) Clumped datasets for
the Southern Asian ancestry. Colors refer to variants in the LD blocks (r2 > 0.5;
different colors represent different LD blocks) and X = presence of a variant in
a specific dataset after the LD clumping analysis. E) Clumped datasets for the
American ancestry. Colors refer to variants in the LD blocks (r2 > 0.5; different
colors represent different LD blocks) and X = presence of a variant in a specific
dataset after the LD clumping analysis. (PDF 88 kb)
Abbreviations
GTEx: Genotype-Tissue Expression; LD: Linkage Disequilibrium; SNP: Single
Nucleotide Polymorphism; TTR: Transthyretin; VCF: Variant Call Format
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